IL15 and neoplasm: These results suggested that biNV-IL-15 could effectively suppress post-surgical tumor recurrence, which may be attributed to the exclusive and valid antitumor immunity induced by spatiotemporally synchronous delivery of IL-15 and tumor antigen.